In a report released yesterday, Marc Wiesenberger from B.Riley FBR reiterated a Buy rating on Zynex (ZYXI), with a price target of $19.75. The company’s shares closed last Monday at $10.98.
Wiesenberger has an average return of 87.6% when recommending Zynex.
According to TipRanks.com, Wiesenberger is ranked #450 out of 5994 analysts.
Currently, the analyst consensus on Zynex is a Moderate Buy with an average price target of $15.88.
See today’s analyst top recommended stocks >>
Based on Zynex’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $2.03 million. In comparison, last year the company had a net profit of $2.62 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
